Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda, which provides Takeda with access to Halozyme’s ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab (marketed globally as ENTYVIO). ENTYVIO is approved for use in adults with moderately to severely active Crohn’s disease or ulcerative colitis. Under the terms of the agreement, Takeda will make...